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Abstract
Background: Cannabinoids, the active components of marijuana, stimulate appetite, and cannabinoid receptor-1 (CB1-R)
antagonists suppress appetite and promote weight loss. Little is known about how CB1-R antagonists affect the central
neurocircuitry, specifically the melanocortin system that regulates energy balance.
Methodology/Principal Findings: Here, we show that peripherally administered CB1-R antagonist (AM251) or agonist
equally suppressed or stimulated feeding respectively in Ay , which lack a functional melanocortin system, and wildtype
mice, demonstrating that cannabinoid effects on feeding do not require melanocortin circuitry. CB1-R antagonist or agonist
administered into the ventral tegmental area (VTA) equally suppressed or stimulated feeding respectively, in both
genotypes. In addition, peripheral and central cannabinoid administration similarly induced c-Fos activation in brain sites
suggesting mediation via motivational dopaminergic circuitry. Amperometry-detected increases in evoked dopamine (DA)
release by the CB1-R antagonist in nucleus accumbens slices indicates that AM251 modulates DA release from VTA
terminals.
Conclusions/Significance: Our results demonstrate that the effects of cannabinoids on energy balance are independent of
hypothalamic melanocortin circuitry and is primarily driven by the reward system.
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Introduction
Obesity is a major health epidemic in developed nations.
Obesity has been implicated in the etiologies of both type 2
diabetes and cardiovascular disease [1]. Recently, a number of
drugs have entered clinical trials as therapies for obesity. A novel
class of drug undergoing clinical trials are the cannabinoid
receptor-1 (CB1-R) antagonists, such as Rimonabant (Accomplia,
sanofi-aventis, SR141716). Cannabinoids, the active components
of marijuana, stimulate appetite and feeding and CB1-R
antagonists reduce feeding in animals and humans [2,3]. Although
Rimonabant is in late-stage clinical trials as a therapy for obesity
and metabolic syndrome, little is known about how CB1-R
antagonists affect the central neurocircuitry that regulates energy
balance.
Central melanocortin pathways play a pivotal role in regulating
appetite and energy balance. Proopiomelanocortin (POMC)
neurons in the arcuate nucleus of the hypothalamus (ARH)
produce the peptide a-MSH which binds to and activates
melanocortin-4 receptors (MC4-R) [4], causing reduced food
intake and increased energy expenditure. MC4-R strongly
regulate body weight and appetite in humans and other species
[4]. Central antagonism of MC4-R increases feeding and obesity
[5,6], whereas central administration of MTII, a potent non-
selective melanocortin agonist, suppresses appetite [7].
Recent work has demonstrated that the CB1-R antagonist
AM251-an analogue of Rimonabant-increases GABAergic inhibi-
tion onto POMC neurons in vitro [8]. This effect would be
expected to increase appetite by decreasing the likelihood of
release of the anorectic peptide a-MSH. However, this is contrary
to the known anorectic action of cannabinoid antagonists. This
paradox suggests that the appetite-suppressing effects of the CB1-
R antagonist are mediated outside of the ARH. Thus, an alternate
possibility is that CB-1 R antagonists suppress appetite via effects
on central reward pathways.
Cannabinoids clearly exert effects on reward and motivation.
The nucleus accumbens (NAc), a region involved in reward, is an
important mediator of appetite [9]. The ventral tegmental area
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(VTA) of the midbrain/pons is a major source of dopamine onto
neurons in the NAc, and palatable food consumption has been
linked to dopamine release within the NAc [10]. Systemic
cannabinoid administration increases the firing rate of dopami-
nergic neurons in the VTA, an effect blocked by CB1-R
antagonists [11,12]. Central administration of the CB1-R agonist
WIN 55,212-2 decreases GABA-mediated inhibitory postsynaptic
currents onto dopaminergic VTA neurons [13]. Thus, it appears
that cannabinoids increase dopaminergic neuronal activity within
the VTA by decreasing inhibitory input onto these cells.
Consistent with the hypothesis that dopaminergic activity in the
VTA regulates feeding, it has recently been reported that ghrelin
increases the firing rate of dopaminergic VTA neurons and that
ghrelin injected into the VTA increases feeding in rats [14].
To investigate whether the melanocortin system is involved in
central cannabinoid effects on appetite, we studied the effects of a
CB1-R antagonist AM251 and a non-selective agonist WIN
55,212-2 on feeding behavior in agouti yellow (Ay) mice. Ay mice
over-express Agouti protein, an endogenous inverse agonist of
MC3 and MC4 receptors, offering a convenient model of
melanocortin antagonism. This study reports that feeding behavior
mediated by the cannabinoid system is independent of the
melanocortin system and that dopaminergic reward pathways
likely play a fundamental role in cannabinoid-induced feeding.
Methods
Animal care and housing
All animal procedures were approved by the Oregon National
Primate Research Center Institutional Animal Care and Use
Committee. Adult male C57BL/6J mice (WT) and Agouti B6.Cg-
Ay/J (Ay; Jackson Labs, Bar Harbor, ME) were individually
housed under a 12 h light/dark cycle and constant temperature
(23uC). Standard chow and water were available ad libitum except
where noted.
Drugs
All drugs were freshly prepared on day of use. AM251 (Tocris)
and WIN 55,212-2 (Tocris) were dissolved in 10% dimethyl
sulfoxide (DMSO) and sterile nonpyrogenic 0.9% NaCl. Drugs
were administered intraperitoneally (IP) in a volume of
0.160.02 mL (according to body weight) for feeding tests. Control
mice received vehicle in a corresponding volume containing 10%
DMSO and sterile saline.
Electrophysiological recording from POMC neurons
Coronal hypothalamic slices containing the arcuate nucleus
(ARH) were prepared from 8 week-old male POMC-EGFP mice
as described previously [15]. This procedure was in accordance
with the National Institutes of Health and the American
Association for Accreditation of Laboratory Animal Care
guidelines and was approved by Oregon Health & Science
University. Briefly, mice were anesthetized with isoflurane and
killed by decapitation. The brain was quickly removed and cooled
in ice-cold artificial cerebrospinal fluid (ACSF) solution of the
following composition (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2/
6H2O, 2.4 CaCl2/2H2O, 1.2 NaH2PO4/H2O, 21.4 NaHCO3
and 11.1 glucose (saturated with 95% O2/5% CO2). A block of
hypothalamic tissue containing the ARH was dissected and
coronal slices (185 mm) were cut with a vibrating slicer (Leica
VT1000S). Slices were stored for at least 1 h in a holding chamber
with ACSF at room temperature and continuously bubbled with
95% O2/5% CO2. Individual slices were submerged in a
recording chamber and superfused continuously with carboge-
nated ACSF at 35uC (3–5 mL/min). To record IPSCs, excitatory
currents were blocked with TTX (1 mM; Sigma), D-AP5
(25 mM;Tocris) and CNQX (10 mM; Tocris). To record EPSCs,
inhibitory currents were blocked with TTX (1 mM; Sigma) and
picrotoxin (10 mM; Tocris).
Recordings were made from arcuate POMC neurons, identified
by bright green fluorescence [15]. Electrode resistances were 2–
4 MV when filled with an intracellular solution of the following
composition, in mM: IPSCs: 70 K- gluconate, 5 HEPES, 0.1
EGTA, 57 KCl, 1.5 MgCl2, 2 (Mg)ATP, 0.5 (Na)GTP; EPSCs:
132 K-gluconate, 4 NaCl, 0.5 CaCl2,. 10 HEPES, 5 EGTA-free, 4
(Mg)ATP, 0.5 (Na)GTP. Whole cell voltage clamp configuration
(Axopatch 200B, Axon Instruments, CA) was used. Data were
filtered at 2 kHz and then sampled at 50–100 kHz by pClamp 8.2
software (Axon Instruments). Data were analyzed using Miniana-
lysis (Synaptosoft, Inc., GA).
Hypothalamic peptide secretion
Static incubation of hypothalamic explants. Twenty four
C57BL/6J ,6 wk-old mice were used. a-MSH release assays was
performed as previously described [16]. Briefly, 2-mm thick
hypothalamic slices taken from the base of the brain (to include the
PVH and ARH) were incubated in artificial cerebrospinal fluid
(aCSF) for 45 min, followed by a 45 min incubation in aCSF (n=
8 hypothalami), or 3 uM CB1 agonist-WIN55212-2 (n = 8
hypothalami) or 3 uM CB1 antagonist AM251(n= 8
hypothalami). Tissue viability was verified by a further
incubation in aCSF containing 56 mM KCl.
Radioimmunoassay. a-MSH radioimmunoreactivity (RIA)
was measured as previously described [16]. The lowest detectable
level that could be distinguished from the zero standard was 0.31
fmol/tube. The intra assay variation (CV%) was determined by
replicate analysis (n = 8) of two samples at a-MSH concentrations
of 2 and 10 fmol/tube, and the results were 9.4% and 8.2%
respectively. The inter assay variation (CV%) was 10.3% and
11.2% for the range of value measured.
Physiological studies
Individually housed mice were habituated to the behavioral
testing procedure by daily IP injections of 0.1 mL sterile saline and
overnight fasting every third day for at least 2 weeks prior to
treatment. Young male (6–8 weeks) Ay (n = 14) and WT (n= 14)
C57BL/6J mice were age- and weight-matched and randomly
assigned to treatment groups. To study the effects of WIN 55,212-
2, mice were not fasted prior to IP injection in the morning. To
determine the effects of AM251, mice were fasted overnight prior
to treatment and given ad libitum access to a predetermined
amount of food immediately after IP injection with AM251
(5 mg/kg) or saline vehicle. Food intake was recorded at 1, 2, 4, 8,
and 24 hour intervals and normalized to wild-type saline control.
VTA cannulation-surgical preparation
Adult (6–8 weeks) WT (n= 8) and Ay (n= 8) mice were
anesthetized with pentobarbital (50 mg/kg, IP). The head of the
mouse was shaved and aligned in a stereotaxic apparatus (Kopf,
CA) such that lambda-bregma plane was horizontal. The head was
cleaned with betadine and an incision made with a sterile scalpel.
A hole was made according to the following co-ordinates for VTA:
3.5 mm caudal, 0.4 mm lateral and 3.0 mm ventral [17]. These
co-ordinates placed the guide cannula (30gauge, 3 mm; Plastics
Inc.) just dorsal to the VTA, allowing injections with minimal
damage to the VTA. The cannula was fixed in place with acrylic
dental cement and two anchoring skull screws. To maintain
patency, a stylet protruding 0.5 mm past the tip of the guide
VTA in Cannabinoid Feeding
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cannula was inserted. After surgery, mice were allowed to recover
for one week, when food intake and body weight returned to pre-
surgery levels. Mice were handled daily and habituated to the
injection procedure for 2 weeks prior to experimental procedures.
Mice were fasted overnight prior to the morning injection of
AM251 (1 mg). Mice were held gently, while the stylet was
removed and an injector was inserted. The injector was 1 mm
longer than the guide cannula. Preliminary experiments in which
dye was injected into the VTA identified an ideal spread of
injection to be 1 ml. Injections (1 ml) were administered slowly over
one minute via a Hamilton syringe and mice were placed in home
cages. The injector was left in the brain for an additional minute
before removal. The stylet was replaced and food intake was
recorded at 1, 2, 4, 8, and 24 hour intervals and normalized to
wild-type saline control. For intra-VTA WIN 55,212-2 (1 mg)
administration, mice were not fasted overnight prior to day of
injection and the above mentioned procedure was carried out. For
intra-VTA saline control administration, mice were injected with a
corresponding volume containing 10% DMSO and sterile saline
and is specified in text as saline for simplicity. To determine the
effects of intra-VTA injections of AM251 on IP cannabinoid
agonist-induced food intake, non-fasted WT mice received intra-
VTA injections of saline (Sal) or AM251 (1 mg) followed by IP
administration of saline or WIN 55,212-2 (1 mg/kg) 15 minutes
later. Conversely, to determine the effects of intra-VTA injections
of WIN 55,212-2 on IP cannabinoid antagonist-induced attenu-
ation of food intake, fasted WT mice received intra-VTA
injections of saline (Sal) or WIN 55,212-2 (1 mg) followed by IP
administration of saline or AM251 (5 mg/kg) 15 minutes later.
Food intake was recorded at 1, 2, 4, 8, and 24 hour intervals and
normalized to saline/saline control. Animals were perfused with
formaldehyde and cannulae placement were histologically verified
at end of experiments. A small number of animals (n = 3) for each
genotype were found to have injection sites outside of the VTA
and these were classified as VTA-missed injections. We achieved
site-specific cannulations 72% of the time for the VTA.
c-Fos immunoreactivity
Male Ay and WT mice were perfused with 4% paraformalde-
hyde 90 min after IP injection with saline-DMSO (n= 3), WIN
55,212-2 (1 mg/kg; n= 3) or AM251 (5 mg/kg; n= 4). In this
study, food was not returned to fasted animals after WIN 55,212-2
treatment. Another group of male Ay and WT mice was perfused
90 min after intra-VTA injection with saline-DMSO (n= 3), WIN
55,212-2 (1 mg; n= 3) or AM251 (1 mg; n= 4). Brains were
removed and 25 mm coronal sections were cut in sets of 4 adjacent
series. Free floating sections were rinsed in 0.05 M potassium PBS
(KPBS), preincubated in blocking buffer, consisting of KPBS
containing 0.4% Triton-X100 (KPBSX) and 2% donkey serum,
for 1 hour. One complete set of sections was incubated in c-Fos
primary rabbit antibody (Santa Cruz Biotechnology, CA;
1:20,000) in blocking buffer for 48 h. Sections were then incubated
with biotinylated donkey anti-rabbit antibody (Jackson Immunor-
esearch, West Grove, PA; 1:600) followed by avidin-biotin
application (Vectastain, Vector Laboratories, Burlingame, CA).
c-Fos IR was visualized using a chromagen label enhanced nickel
chloride. Tissue sections were mounted on gelatin-coated glass
slides, counterstained with cresyl violet and coverslipped.
For immunohistochemistry of c-Fos and EGFP, detection of c-
Fos was carried out as described above in POMC-EGFP mice.
Following washes after chromagen detection, sections were
incubated in rabbit anti-GFP antibody (1:10,000) overnight at
4uC. Sections were then incubated with fluorescein-conjugated
donkey anti-rabbit secondary antibody (Jackson Immuno Re-
search, 1:200) in 1 M KPBS for 2 hours. Sections were then
washed, mounted and coverslipped using Fluoromount-G (South-
ern Biotech).
For double-labeling of c-Fos and orexin or MCH, two complete
sets of sections were used. One set was incubated with c-Fos
antibody and a goat polyclonal antibody (Santa Cruz Biotechnol-
ogy, sc-8070; 1:5000) directed against the C-terminus of the
human orexin-A peptide. The other set was incubated with c-Fos
antibody and a chicken polyclonal antibody (Bachem, T-1506;
1:3000) directed against the full length 18-residue human MCH
peptide for 1 hour at room temperature followed by 48 hr at 4uC.
Detection of c-Fos was carried out as described above. Following
washes after chromagen detection, sections were incubated with
fluorescein-conjugated donkey anti-goat or rhodamine-conjugated
donkey anti-chicken fluorescent secondary antibodies (Jackson
Immuno Research, 1:200) in 1 M KPBS for 2 hours. Sections
were then washed, mounted and coverslipped using Fluoromount-
G (Southern Biotech).
c-Fos quantification. Depending on treatment, 9–11 brain
regions and 4–6 sections for each region were examined using light
microscopy (Nikon Eclipse E800 series microscope. Images were
captured using a CoolSnapHQ camera system and Metamorph
software (using 10Xobjective). Captured images were subsequently
analyzed using Adobe Photoshop software, whereby a grid was
placed over regions of interest and the number of labeled cells
within a standardized area was counted manually by an
investigator blind to the treatment group. A neuron was
classified as c-Fos-positive when the nucleus was intensely
stained black in colour and appeared either round or oval.
Values were expressed as the mean number of c-Fos positive cells
per section for each region. Regions analyzed were anatomically
matched across all animals.
The number of c-Fos, EGFP-positive cells or double-labeled (c-
Fos and EGFP) cells were counted from 5 sections spanning the
ARH, using both light microscopy for c-Fos and fluorescence for
EGFP. Values are shown as the percentage of EGFP positive cells
expressing c-Fos.
The number of orexin or MCH neurons or double-labeled
(orexin/c-Fos or MCH/c-Fos) cells were counted from 4–6
sections spanning the LH, using both light microscopy for c-Fos
and fluorescence for orexin or MCH. Values are shown as the
percentage of orexin neurons expressing c-Fos.
Slice Recordings: Carbon fiber amperometry
Sprague Dawley male rats (3–5 weeks) were anesthetized with
ketamine (200 mg/kg IP)/xylazine (20 mg/kg IP). Upon removal,
the brain was immediately placed into ice-cold carbogenated (95%
O2, 5% CO2) dissection solution containing (in mM): 210 sucrose,
3.5 KCl, 1 CaCl2 dihydrate, 4 MgCl2 hexahydrate, 1.25
NaH2PO4 hydrate, 10 glucose, and 26 NaHCO3. Coronal slices
(300 mm) containing the nucleus accumbens, were cut using a
vibratome. Following 1 hr recovery in carbogenated ACSF (in
mM, 124 NaCl, 2.0 KCl, 1.25 KH2PO4, 2.0 MgSO4, 25
NaHCO3, 1.0 CaCl2, 11 glucose [pH 7.3]), each slice was
transferred into a recording chamber maintained at 37uC. Slices
were continually perfused with ACSF (1 ml/min). Carbon fiber
amperometry was used to record the release of neurotransmitter.
A disk carbon fiber electrode, 5 mm in diameter, was placed in the
posterior nucleus accumbens shell at a depth of ,50 mm. The
reference electrode (Ag/AgCl wire) was inserted into the ACSF
bath. Voltage was set to +700 mV (Axopatch 200B.). The bipolar
stimulating electrode (diameter 0.005 inch—MS 303/3, Plastics
One, Inc.) was placed within a distance of 200 mm from the
carbon fiber electrode. A constant monophasic current stimulus
VTA in Cannabinoid Feeding
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(delivered by Isoflex stimulus isolator, AMPI Inc., controlled by
Grass Instruments S88 Stimulator) was applied through the
bipolar stimulating electrode with the following stimulation
parameters: single rectangular pulse for 2 msec, +500 mA
amplitude. For each slice, five single pulses were given in the
nucleus accumbens shell at five-minute intervals while in the
ACSF bath, then the slice was washed in 3 mM AM251 (in ACSF)
for 30 min. After the wash, five more single pulses in five-minute
intervals were given at the same location. Amperometric electrode
recordings were monitored and quantified by a locally written
routine on the Superscope II platform (GW Instruments). Data
was acquired at 50 kHz and digitally postfiltered at 1 kHz.
Background-subtracted cyclic voltammograms calibrate the elec-
trodes and identify the released substance as DA. Mean of signal
amplitudes, widths, and number of molecules in ACSF were
compared to those following the 3 mM AM251 wash by 1-way
ANOVA.
Statistical Analysis
For electrophysiological data, paired Student’s t test was used
for comparison of two groups: 10 min of stable baseline with
10 min after treatment. The F-test was used to compare
differences in the slopes derived for interevent interval and
amplitude analysis. For a-MSH IR, data were analyzed by 1-way
ANOVA, followed by Bonferroni’s Multiple Comparison Test.
For physiological analysis, data are presented as fraction of control
and analysed by ANOVA. For c-Fos immunohistochemistry, two-
way ANOVA was used to examine genotype versus treatment
effects. For double-labeling study, counted cells were expressed as
percentage of orexin positive c-Fos cells and significance between
treatment groups was calculated via 2-way ANOVA. Data were
expressed as mean6SEM, p,0.05 was considered significant.
Results
AM251 increases the frequency of inhibitory
postsynaptic currents onto POMC neurons
To directly examine the role of cannabinoid agents on
arcuate melanocortin circuitry, we examined the effect of
AM251 (3 mM) and WIN 55,212-2 (3 mM) on POMC neurons
using POMC-EGFP mice [15]. In patch-clamp recordings from
visually identified arcuate POMC neurons, the CB1-R
antagonist AM251 increased the frequency of GABAergic
inhibitory postsynaptic currents (IPSCs) onto POMC neurons
(41%, 1.761.1 and 2.461.3 Hz, baseline and AM251,
respectively; n = 7, p,0.05, Figure 1A, B, E), with no effect
on IPSC amplitude (49.6610.1 and 46.0610.9 pA, baseline
and AM251, respectively, Figure 1C). AM251 produced no
change in IPSC kinetics (Figure 1D). In addition, AM251 did
not significantly affect the frequency of excitatory postsynaptic
currents (EPSCs; 0.560.1 and 0.6360.12 Hz, baseline and
AM251, respectively), or EPSC amplitude (22.463.6 and
23.663.1pA, baseline and AM251 respectively, n = 7, data
not shown). Conversely, the CB1-R agonist WIN 55,212-2
decreased the frequency of IPSCs onto POMC neurons (38%,
1.360.5 and 0.860.3 Hz, baseline and WIN 55,212-2
respectively, n = 5, p,0.05) with no effect on amplitude
(38.669.2 and 37.669.2 pA, baseline and WIN 55,212-2,
respectively, data not shown). Curiously, WIN 55,212-2 also
decreased the frequency of EPSCs onto POMC neurons (64%,
2.560.8 and 0.960.4 Hz, baseline and WIN 55,212-2,
respectively; n = 4, p,0.05), with no effect on amplitude
(25.264.1 and 22.263.5 pA, baseline and WIN 55, 212-2,
respectively, data not shown). Our findings that a CB1-R
antagonist inhibits the activity of anorectic POMC neurons are
consistent with those of Hentges et al. (2005) [8]. However,
these findings are inconsistent with the known anorectic effects
of CB1-R antagonists. In addition, the CB1-R agonist
decreased the frequency of both inhibitory and excitatory
currents onto POMC cells, suggesting a negligible effect on
overall POMC neuronal activity. Thus, it seems unlikely that
cannabinoids’ dramatic effects on feeding can be explained on
the basis of their effects on POMC neurons alone. We further
measured the release of a-MSH from hypothalamic explants
incubated with AM251 or WIN 55, 212-2 to test the sensitivity
of POMC neurons to cannabinoids. There was no significant
difference in a-MSH levels in explants incubated with AM251
or WIN 55, 212-2 compared to explants incubated with aCSF
(Figure S1). In light of above results, immunohistochemical
staining for c-Fos activation and POMC-GFP expression were
analyzed in the ARH of IP AM251 and saline treated animals.
c-Fos expression was increased significantly by AM251 between
saline and treated mice (p = 0.0012) (Figure S2). POMC-EGFP
cell counts are not significantly different between saline and
treatment groups. There was a trend towards an increase in c-
Fos and POMC-EGFP co-localization in vehicle (n = 6; 6%)
and AM251 treated group (n= 6; 13%; p.0.05, paired t test)
but this was not significant and lends support to the
electrophysiological and radioimmunoassay data above, that is,
the activation observed in the ARH with AM251 was not
robust.
Cannabinoid modulators similarly regulate food intake in
Ay and WT mice
The role of the melanocortin circuitry in cannabinoid-
modulated feeding was next tested by assessing differences in
feeding behavior between wildtype (WT) and Ay mice. Intraper-
itoneal administration of the cannabinoid agonist WIN 55,212-2
(1 mg/kg) similarly increased 1-hour food intake by 80% in both
Ay and WT mice (F(3,51) = 9.40, P,0.0001; Figure 2A).This effect
was transient, no longer significant by the 4, 8, or 24 hour
timepoints. At doses greater than 1 mg/kg (2.5 and 5 mg/kg),
mice were partially supine and inactive for at least 2 hours
postinjection, compared to saline-injected mice (data not shown).
In order to investigate feeding inhibition by the cannabinoid
antagonist, mice were fasted overnight. Intraperitoneal (IP)
administration of AM251 significantly decreased 1-hour food
intake in both Ay and WT mice compared to saline (F(3,51)
= 16.53, P,0.0001; Figure 2B). Similar to WIN 55,212-2, the
effects of AM251 were transient; the reduction in food intake was
absent by 8 h postinjection. Likewise, both genotypes decreased
fasting-induced re-feeding 47% in response to AM251 (5 mg/kg,
Figure 2B).
Central administration of the cannabinoid agonist and antag-
onist produced comparable responses to those of peripheral
administration. Intra-VTA WIN 55,212-2 administration in-
creased 1-hour food intake in nonfasted Ay and WT mice
(F(3,31) = 3.98, P= 0.016; Figure 2C) and AM251 decreased 1-
hour food intake in fasted Ay and WT mice (F(3,27) = 3.98,
P= 0.017; Figure 2D) compared to saline treatment and intra-
VTA missed treated groups. The fact that Ay mice respond
normally to peripheral and central AM251 indicates that
endogenous antagonism of MC3/4 receptors (in Ay mice) does
not disrupt feeding responses to cannabinoids.
To further investigate the role of the VTA as a potential
mediator of cannabinoid-induced feeding, we assessed whether
disrupting cannabinoid signaling in the VTA would prevent
systemic cannabinoid agonist from inducing hyperphagia. Intra-
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VTA AM251 prevented the increase in food intake induced by IP
WIN 55,212-2 in non-fasted WT mice (F(3,27) = 18.67, P,0.0001,
Figure 2E), demonstrating that peripheral cannabinoid-induced
feeding requires CB1-R activation in the VTA. In contrast in
fasted WT mice, intra-VTA WIN 55,212-2 did not block the
feeding inhibition induced by IP AM251 (F(3,25) = 23.45,
P,0.0001), Figure 2F).
Peripheral administration of WIN 55,212-2 or AM251
reveals similar central c-Fos staining in Ay and WT mice
We performed c-Fos immunohistochemistry to determine the
activation of central circuitry after peripheral (IP) administration
of WIN 55,212-2 and AM251 in Ay and WT mice (Table 1, Figure
S3). c-Fos expression was analyzed in the NAc, ARH, PVH, LH,
CeA, VTA, LC, PBN and NTS. The CB1-R agonist WIN 55,212-
2 substantially increased c-Fos IR in the LC, PBN and NTS, and
modestly increased c-Fos IR in forebrain structures such as the
PVH and CeA in both Ay and WT mice. Intraperitoneal AM251
produced significant c-Fos IR in the ARH, PVH, LH, CeA and
the shell of the NAc, and also in hindbrain regions such as the LC,
PBN and NTS in Ay and WT mice. Peripheral AM251 also
increased c-Fos IR in regions of the brain associated with reward,
such as the shell of the NAc and CeA. The core of the NaC
expressed low c-Fos IR with peripheral WIN 55,212 or AM251
(data not shown). Peripheral WIN 55,212-2 or AM251 did not
induce significantly different patterns of cellular activation
between the genotypes, indicating that the cannabinoid agonist
and antagonist activate similar brain regions despite the absence of
a functional melanocortin system. These data suggest that
cannabinoids may produce their effects on feeding by activating
both homeostatic regulators of feeding such as the LH and PVH
and reward-based areas such as the CeA and NAc that integrate
and relay various properties of food to drive feeding behavior.
Intra-VTA WIN 55,212-2 produces significant c-Fos IR in
hindbrain and forebrain areas involved in feeding and
reward in Ay and WT mice
To further examine the potential role of reward circuitry in
cannabinoid effects, we injected cannabinoids directly into the
VTA (Table 1, Figure S4). Immunohistochemical staining for c-
Fos expression was analyzed in the NAc (shell and core), bed
nucleus of the stria terminalis (BST), ARH, PVH, LH, DMH,
ventromedial hypothalamus (VMH), CeA, VTA, LC, PBN and
NTS. There were no significant differences in c-Fos IR between
central WIN 55212-2 or AM251 treatment between genotypes.
Similar to peripheral administration, central (intra-VTA) WIN
55,212-2 increased c-Fos IR in the LC, PBN and NTS in both
genotypes, suggesting that the agonist either directly activates
neurons or removes inhibitory tone onto cells within these areas.
Compared with peripheral administration, intra-VTA AM251
produced more staining in hypothalamic structures such as the
LH, DMH, and VMH, possibly indicating downstream activation
of these regions from the VTA. Central AM251 produced no
significant activation in the LC, PBN, and NTS. Interestingly,
there was a trend for increased c-Fos staining in the LH with intra-
VTA administration of both the cannabinoid agonist and
antagonist (Table 1), suggesting that distinct cell phenotypes,
possibly orexin and melanin-concentrating hormone (MCH), may
be activated.
We further carried out double-labeling for c-Fos and orexin or
MCH. Central CB1-R agonist administration produced a
significant percentage of c-Fos positive orexin neurons in the LH
(33.362.2% WT; 29.164.1% Ay , p,0.05, Figure 3B, E, F),
compared to saline treatment (1.260.7% WT; 4.662.3% Ay,
Figure 3B, C, D). After central CB1-R antagonist administration, a
smaller percentage of orexin neurons co-localized with c-Fos IR in
the LH (18.562.7% WT; 9.361.4% Ay, p,0.05, Figure 3B, G,
Figure 1. Effect of AM251 on POMC neurons. A, AM251 increased the IPSC frequency onto POMC neurons: time-effect plot of IPSC frequency
from a representative cell in presence of AM251 (3 mM; shaded region); B, Cumulative plot of interevent interval or C, IPSC amplitude from the same
cell as A. D, Examples of raw data showing IPSCs before, during and after bath application of AM251 (3 mM; left) with representative kinetics of IPSC
(right inset) and conductances before (black) and during peak antagonist effect (red). E, Summary of effect of AM251 on normalized IPSC frequency.
(* p ,0.05, when compared with baseline; ns,not significant).
doi:10.1371/journal.pone.0002202.g001
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H), compared to saline treatment. Co-localization of c-Fos with
MCH was not observed with either central CB1-R antagonist or
agonist treatment in WT or Ay mice (data not shown). Intra-VTA
cannabinoids activate appetite-stimulating orexin neurons and not
MCH neurons, suggesting a specific delineation of roles with
respect to regulation of cannabinoid effects.
AM251 increases evoked dopamine release in coronal
nucleus accumbens slices
Because the reward circuitry is more likely than the melano-
cortin circuitry to be responsible for the effects of cannabinoids on
feeding [18–21], we tested how cannabinoids affect dopamine
release from the VTA. We directly assessed evoked dopamine
release from NAc terminals in acute slice preparations from rats
using electrochemical methods [22] (Figure 4). A carbon fiber
electrode was inserted into the NAc shell to collect amperometric
recordings from dopaminergic axons arising from the VTA. The
current produced by the electrochemical oxidation of extracellular
dopamine measures dopamine release kinetics in real time. As
shown in Figure 4A, electrical stimulation by an adjacent bipolar
stimulating electrode increased dopamine release from NAc
terminals. After bath application with the CB1-R antagonist
AM251 (3 mM), electrically evoked dopamine release increased
significantly (3.8610661.26106 and 21.6610663.66106 mole-
cules, ACSF and AM251, respectively, F(1,24) = 13.35, P = 0.0005;
Figure 4B). AM251 also significantly increased evoked signal
amplitude (20.261.8 and 7.960.6 pA, F(1,24) = 31.07, P,0.0001)
and evoked signal width (1.660.4 and 0.560.2 sec, AM251 and
ACSF respectively, F(1,24) = 5.09, P= 0.033; Figure 4C, D). This
shows that AM251 is regulating stimulated DA release from VTA
terminals in the NAc.
Figure 2. Effects of cannabinoid agonist and antagonist on food intake. A, IP WIN 55,212-2 increased 1-hour food intake in both Ay and WT
mice; B, IP AM251 decreased food intake in both Ay and WT mice; C, Intra-VTA WIN 55,212-2 increased food intake and D intra-VTA AM251 decreased
food intake in both genotypes. Food intake data presented as fraction of control (*p ,0.05, when compared with saline). Effect of intra-VTA AM251
on feeding induced by peripheral WIN 55,212-2; E, Intra-VTA AM251 blocked feeding induced by IP WIN 55, 212-2 in WT mice (a: p ,0.001 compared
to saline/saline (Sal/Sal); b: p,0.001 compared to intra-VTA saline/IP WIN 55,212-2 treatment group); F, IP AM251 causes similar reduction in response
to intra-VTA WIN 55,212-2 administration (a; p,0.001 compared to (Sal/Sal); c:.p,0.001 compared to intra-VTA WIN 55,212-2/IP AM251 treatment
group).
doi:10.1371/journal.pone.0002202.g002
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Discussion
Cannabinoid effects on feeding are unaffected by the absence of
a functional melanocortin system–no differences were observed
between WT and Ay mice in the feeding responses to either a
CB1-R agonist or antagonist. Regional brain activation by either
central (intra-VTA) or peripheral (IP) cannabinoid administration
was nearly indistinguishable between genotypes. Our main
findings demonstrate that functional central melanocortin circuitry
is not required for cannabinoid-induced modulations in feeding
behavior, but rather that activation of dopaminergic reward
circuitry is involved in cannabinoid’s effect on feeding.
Our observation that a CB1-R antagonist related to Rimona-
bant increased inhibitory synaptic currents onto identified POMC
cells in vitro is contrary to what would be predicted based on the
known anorectic role of POMC neurons and the demonstrated
effects of cannabinoid agonists and antagonists on feeding. If
feeding inhibition induced by the CB1-R antagonist was mediated
by increasing a-MSH release (therefore stimulating MC4-R), we
would predict that AM251 would produce either a decrease in
IPSC frequency or an increase in EPSC frequency onto POMC
cells–which was not observed. Additionally, the CB1-R agonist
WIN 55,212-2 reduced both spontaneous inhibitory and excitato-
ry inputs onto POMC neurons, suggesting that cannabinoids may
have little net effect on the excitability of POMC neurons. Our
findings are consistent with those of Ho and colleagues in which a
dose-dependent decrease in EPSC frequency was found with WIN
55,212-2 onto POMC neurons in the guinea pig ARH [23]. In
contrast with their findings, we conclude that the net effect of WIN
55,212-2 onto arcuate POMC neurons is likely negligible since the
agonist also reduces the frequency of spontaneous IPSCs onto
these neurons. We found that cannabinoids did not effect a-MSH
release from POMC neurons, and co-localization of c-Fos and
POMC-EGFP neurons in response to IP AM251 was marginal.
Pathways other than the melanocortin system are likely respon-
sible for feeding effects induced by cannabinoids. This conclusion
is corroborated by our feeding studies in which cannabinoids are
equally efficacious in WT and Ay mice.
Rimonabant and AM251 reliably decrease food intake and
body weight in obese fa/fa rats, and both ob/ob and Ay mice
[24,25], often with greater effects than in lean littermates. In rats,
Verty et al. (2004) demonstrated that central THC (a CB1-R
agonist) increased food intake and central a-MSH decreased food
intake, but that THC-induced feeding was not inhibited by a-
MSH [26]. However, Verty et al. (2004) further found that a CB1-
R antagonist (SR 141716) reduced food intake induced by a
central MC4-R antagonist (JKC-363). In contrast, we demonstrate
that AM251 attenuates food consumption in Ay mice (a functional
model of MC4-R antagonism) the same amount as WT mice.
Signalling through MC4R is abolished in both Ay and MC4R
knockout mice; as with all genetic modifications, developmental
compensation cannot be excluded. There are at least three likely
reasons for this discrepancy between our data and that of Verty et
al. (2004). The first is the mechanism of blockade of MC4
receptors. In the Ay mice, Agouti protein binds to the MC4-R and
stabilizes it in its inactive conformation, rather than simply
blocking the receptor in a competitive fashion [27]. Second, to
ensure the VTA would be activated by central cannabinoids, we
injected agents directly into the VTA, whereas Verty et al.(2004)
administered agents into the lateral ventricle. Third, different
Table 1. Effect of peripheral (IP) and central (intra-VTA) WIN 55,212-2 and IP AM251 on c-Fos IR in Ay and WT mice.
NAc shell ARH PVH LH DMH VMH CeA VTA LC PBN NTS
IP Administration
WT Saline 0.960.5 160.5 0.660.3 2.261.3 3.561.5 1.660.7 3.462.3 2.561.3 461.2
WIN 55,212-2 761.6 861.8 1563.9*** 9.862.4 2262.5*** 5.761.4 3163.8*** 4469.5*** 3063.5***
Ay Saline 361.3 160.4 3.661.8 160.4 1.460.9 0.760.5 761.4 1.360.6 4.260.8
WIN 55,212-2 1163.1 761.7 964 461.9 3063.9*** 4.261.2 2261.4** 3465.5*** 37 64.7 ***
WT Saline 0.760.4 560.7 1061.4 1661.8 762.6 260.6 763.2 0.860.4 762.5
AM251 1764.3*** 1462.3* 1462.7 2363.5 2264.6** 961.7 2261.5* 3069.1*** 1666.3
Ay Saline 1866 260.4 761.2 1161.6 361.6 160.3 460.4 1.560.5 1064
AM251 3663.8***{{{ 1262** 2162.7*** 2963*** 962.4{{ 962.2 1860.5 6366.2***{{{ 3363.8***{{
Intra-VTA Administration
WT Saline 261.5 462.7 763.1 764.1 361 460.5 462 260.7 260.3 260.8 762.2
WIN 55,212-2 2262.8** 1160.8 1964.6 2764.9 660.1 860.5 861.4 560.4 1763.4** 2163.6** 1663.8
Ay Saline 361.3 662.2 360.7 462 663.5 4.563.5 461.5 260.8 9.463.9 662.1 561.9
WIN 55,212-2 1263.5 961.3 2865.6*** 2461.7 1260.5 1461.5 1563.5 661.0 3765.3***{{{ 3862.5*** {{ 3365.2***{{{
WT Saline 461.4 562.1 1364.7 964 1264.5 1364.1 360.5 860.8 161 161 361.5
AM251 661.2 1062.6 2565.5 2562.7* 5065.5** 3963.1** 1262.5 860.9 1863.2 864.6 762
Ay Saline 562.1 962.9 1067.1 560.7 762.4 1063.7 360.75 461.7 1465.6 1464 9 63 .7
AM251 863.2 1463.5 1664.1 1665 3961.0** 2467.2 1161.5 660.9 2663.2 2263.9 1262.3
Male Ay and WT mice were perfused with 4% paraformaldehyde 90 min after IP injection with saline-DMSO (n = 3), WIN 55,212-2 (1 mg/kg;n = 3) or AM251 (5 mg/kg;
n = 4). Another group of male Ay and WT mice was perfused 90 min after intra-VTA injection with saline-DMSO (n = 3), WIN 55,212-2 (1 mg; n = 3) or AM251 (1 mg; n = 4).
Immunohistochemical staining for c-Fos expression in nucleus accumbens, NAc (shell), arcuate nucleus (ARH), paraventricular nucleus (PVH), lateral hypothalamus (LH),
dorsomedial hypothalamus (DMH), ventromedial hypothalamus (VMH), central amygdala (CeA), ventral tegmental area (VTA), locus coerulus (LC), parabrachial nucleus
(PBN) and nucleus of the solitary tract (NTS). Results are expressed as mean6SEM.* p ,0.05, ** p ,0.01, *** p ,0.001 compared to saline; { represent statistical
comparisons between WT and Ay mice; { p ,0.05,{{ p ,0.01, {{{ p ,0.001.
doi:10.1371/journal.pone.0002202.t001
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Figure 3. c-Fos and orexin co-localization in the LH in Ay and WT mice after intra-VTA injection with saline, WIN55,212-2 or AM251.
A, Coronal cross-section showing where manual counts of positively stained neurons were made (blue shaded region). c-Fos staining indicated in
brightfield images and orexin neurons shown in fluorescence (FITC-green). Arrows indicate co-localised neurons for c-Fos (black arrows) and orexin
(yellow arrows) in WT mice. B, G, H, Small percentage of orexin neurons co-localized with c-Fos activation in the LH with central AM251
administration. B, E, F, A greater percentage of c-Fos positive orexin neurons was found with central WIN 55,212-2 treatment compared to B, C, D,
saline treatment. Scale bar, 100 mm.
doi:10.1371/journal.pone.0002202.g003
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species used for investigation of the circuitry may also account for
the different results.
In humans, cannabinoids are involved in food orosensory-based
reward. Subjects increase consumption of highly palatable foods in
response to marijuana [28]. In animal models, it is well established
that activation of reward pathways provides both a strong
influence on food choice [29,30] and feeding behavior [31],
associated with an increase in dopamine release in the NAc [32].
Here, we report that peripheral WIN 55,212-2 and AM251
induced c-Fos staining in structures such as the NAc shell, PVH,
LH, CeA, LC, PBN, and NTS in mice. Little or no c-Fos IR was
observed in the prefrontal cortex, caudate putamen, BST, or
VTA-areas of AM251-induced c-Fos IR in rats [33–35]. Our
results indicate no clear genotypic differences in response to
peripheral WIN 55, 212-2 or AM251 treatment. We observed
strong c-Fos expression induced by IP AM251 in the NAc shell,
LH, CeA, and NTS, suggesting that these nuclei form a functional
circuit through which cannabinoids mediate changes in food
intake. Cannabinoids may produce their effects on feeding by
recruiting various anatomical sites-inside and outside the hypo-
thalamus-that integrate and relay gustatory, sensory and reward
properties of food [36].
In our study, intra-VTA WIN 55, 212-2 injection increased c-
Fos activation in the PVH, LH, PBN, and NTS. Intra-VTA
AM251 significantly increased Fos-IR in several hypothalamic
nuclei, including DMH and VMH, which was not observed with
peripheral AM251, suggesting that cellular activation within these
regions was due to downstream activation of the VTA. The DMH
and VMH are targets of converging orexigenic and anorexigenic
pathways [37], and are known to regulate food intake by
influencing metabolic, hormonal, and endocrine responses relating
to the nutritional state of the organism [38]. Neuronal DMH
activation leads to increased sympathoexcitation and specifically
brown adipose tissue (BAT) thermogenesis [39]. Furthermore,
activation of neurons in the LH increase sympathetic nerve drive
to BAT, in a pathway dependent on activity from neurons in the
DMH [40]. VMH administration of anandamide, an endogenous
cannabinoid, induces feeding via CB1-R activation [41]. Down-
stream neuronal activation in both VMH and DMH by intra-
VTA AM251 may promote weight loss via simultaneously
suppressing appetite (i.e., VMH activation) and by a sympathet-
ically-mediated increase in metabolic activity (i.e., DMH activa-
tion).
Lesion studies have also indicated that the LH regulates
ingestive behavior [42]. Within the LH, two neuropeptides,
MCH and orexin, are localized to distinct neuronal populations.
Orexin neurons in the LH project to the VTA and orexin
increases the firing rate of VTA neurons [43]. Endogenous orexin
Figure 4. Effect of AM251 on electrically stimulated dopamine release from the NAc shell. A, Representative amperometric traces of
electrical stimulation-evoked dopamine release in the nucleus accumbens shell from coronal slices of Sprague Dawley rats. A 0.5 mA electrical pulse
lasting 2msec (arrow) was used as a stimulant with an interstimulus interval of 5 min to allow for full recovery. Data was recorded at 50 kHz and
filtered at 1 kHz. The top trace is representative of the ACSF group and the bottom trace is representative of the evoked dopamine response after a
30 min 3 mM AM251 wash. B, The mean number of evoked dopamine molecules significantly increased from 3.8610661.26106 in ACSF to
21.6610663.66106 after 3 mM AM251 (n = 11 stimulations in ACSF, n = 15 stimulations after 3 mM AM251 in 3 slices per group from 3 animals,
**p,0.01 by 1-way ANOVA). C, The mean stimulated signal amplitude increased significantly from 7.960.6 pA in ACSF to 20.261.8 pA in 3 mM
AM251 (**p,0.01). D, The mean stimulated signal width increased significantly from 0.560.2 seconds in ACSF to 1.660.4 seconds in 3 mM AM251
(*p,0.05). All values are expressed as mean6SEM.
doi:10.1371/journal.pone.0002202.g004
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signaling to VTA dopaminergic neurons is critical for the
expression of motivated behaviors [44]. Cannabinoids have been
shown to modulate the electrophysiological activity of orexin and
MCH neurons [45,46]. Consistent with orexin’s recognized
appetite-stimulating effect [47], we found a significant amount of
co-localization of orexin and c-Fos (30%) after central WIN 55,
212-2 administration. However, these results are inconsistent with
those of Huang et al. (2007). In acute slice preparations of mouse
hypothalamus, Huang et al. (2007) found that WIN 55,212-2
inhibited orexin neurons via decreasing excitatory synaptic inputs.
We observed a small percentage of orexin neurons (10%) that co-
localized with c-Fos in the LH after central AM251 administra-
tion, consistent with Huang et al’s (2007) finding that AM251
increased the activity of orexin neurons. In contrast with Huang et
al. (2007) and Jo et al. (2005) in vitro studies, MCH IR neurons
were not activated by in vivo central WIN 55,212-2 administra-
tion. In vitro slice techniques are more sensitive than c-Fos IR, and
it is possible that we were unable to detect activation of MCH
neurons. Our detection of orexin neuron activation by WIN
55,212-2 may reflect that the drug was given in awake cannulated
mice versus direct application in acute slice preparations and we
used doses that did not alter non-feeding behavior. At any rate, we
speculate that the two groups of orexigenic neurons may possibly
play distinct roles with regards to modulation of cannabinoid-
induced effects. Clearly, orexin from the LH appears to provide a
feedback system into the VTA, possibly activating dopaminergic
systems.
Our findings show that the CB1-R antagonist AM251 increased
electrically evoked release of DA in NAc, in acute slices. It has
been shown that CB1-R antagonists in the VTA decrease activity
of DA neurons induced by a CB1-R agonist [11,12]. Thus, the
effects of CB1-R antagonist in our preparation are complex to
interpret, especially in the absence of a clear paradigm of how DA
signaling regulates reward and satiety.
At the behavioral level, AM251 suppresses food intake in mice
[48]. Increased dopamine in the NAc during feeding and at the
end of the meal has been shown as a signal for meal termination
and satiation [49]. Thus, increased dopamine release in the NAc
may contribute to the anorexic effect of AM251.
Rats with high motivation to initiate feeding (underweight food-
deprived rats and dietary obese rats) have low, not high, basal
extracellular dopamine in the NAc [50–52]. While dopamine is
essential for feeding, excess dopamine (as, for example, induced
pharmacologically by AM251 in our study) inhibits feeding. This
has been previously demonstrated by (a) using amphetamine to
flood synapses with dopamine [50], (b) preventing dopamine
uptake with cocaine or other dopamine transporter inhibitors [51],
or (c) administering nonspecific dopamine receptor agonists
(apomorphine) [53]. All of these drugs are appetite suppressants
and linked to higher dopamine levels in the synapse.
In awake, behaving rats, Cheer et al. (2004) [54], using
amperometry, demonstrated that the CB1-R agonist WIN
55,212-2 increased the frequency of dopamine transients, while
decreasing the amplitude of evoked DA release in the NAc, an
effect opposite to and compatible with the increase in amplitude of
evoked DA release induced by AM251 in the present study. These
data suggest that a sustained increase in DA cell body firing rate
eventually depletes the readily available pool of DA-containing
vesicles for release in response to electrical stimulation. Therefore,
an alternative interpretation of our data is that AM251 acutely
decreased the activity of VTA DA neurons without decreasing DA
synthesis. This would be accompanied by an increase in DA
quantal size which we essentially detected with electrical
stimulation of terminals in the NAc. There is not a clear paradigm
of how stimulation of DA exocytosis in the NAc regulates food
intake. However, it is clear that DA release kinetics can
significantly impact DA signaling [55]. Here, we show that
intra-VTA CB1-R antagonists inhibit food intake and increase
evoked NAc DA release, indicating that DA may well be involved
in modulating cannabinoid activity in the reward circuitry but this
is not explicitly shown by our data here. Clearly, we do not address
issues pertaining to basal DA tone, which is also a critical
component of DA signaling in the mesoaccumbal pathways.
Our main result is that cannabinoids exert their effects on
feeding via pathways that are independent of the melanocortin
system. While other homeostatic hypothalamic regions such as
the PVH, LH, VMH, and DMH are likely involved in
mediating cannabinoid-induced feeding behavior, one of the
key sites for transducing feeding signals–the arcuate nucleus–is
likely not critical. Rather, the VTA-NAc axis may well drive
feeding behavior induced by cannabinoids in both Ay and WT
mice. In addition, other reward-based sites such as the CeA and
NAc are activated by peripheral cannabinoids in both Ay and
WT mice. An intra-VTA CB1-R antagonist inhibits food intake,
blocks the effect of systemic CB1 agonist, and local slice
application of AM251modifies evoked DA release in the NAc,
lending support to the hypothesis that activation of mesolimbic
pathways is sufficient for many of effects of the cannabinoid
antagonists.
Supporting Information
Figure S1 Effects of WIN 55,212-2 and AM251 on a-MSH
release from POMC neurons of the hypothalamus. There was no
significant effect on a-MSH release (fmol/ml) from POMC
neurons by cannabinoids. All values are expressed as mean6SEM.
Found at: doi:10.1371/journal.pone.0002202.s001 (0.14 MB TIF)
Figure S2 Effects of IP AM251 on c-Fos and POMC-EGFP co-
localization in POMC-EGFP mice. ARH slices were stained for
c-Fos and EGFP expression. c-Fos staining indicated in brightfield
images and POMC-EGFP neurons shown in fluorescence (FITC-
green). Red arrows indicate c-Fos and POMC-EGFP co-localized
cells. A, c-Fos activation in response to IP saline; B, c-Fos and
POMC co-localization in response to IP saline; C, c-Fos
activation in response to IP AM251 (5 mg/kg); D, c-Fos and
POMC co-localization in response to IP AM251. Scale bar,
100 mm. Quantification of immunohistochemical staining for c-
Fos and POMC-EGFP co-localization in the ARH. E, c-Fos
expression was increased significantly by AM251 between IP
saline and AM251 treated groups; F, POMC-EGFP cells counts
are not different between saline and AM251; G, Percentage of
POMC cells expressing c-Fos IR. All values are expressed as
mean6SEM.
Found at: doi:10.1371/journal.pone.0002202.s002 (1.73 MB TIF)
Figure S3 Representative photomicrographs showing c-Fos IR
in response to IP saline, WIN 55212-2 and AM251 administration
in Ay mice. A, B, C, c-Fos activation in response to saline in the
NAc, PVH and NTS. D, E, F, Increased c-Fos IR in response to
IP WIN 55,212-2. G, H, I, c-Fos IR in response to IP AM251. ac,
anterior commissure; 3V, third ventricle, AP, area postrema. Scale
bar, 100 mm.
Found at: doi:10.1371/journal.pone.0002202.s003 (3.03 MB TIF)
Figure S4 Representative photomicrographs showing c-Fos IR
in response to intra-VTA administration of AM251 in the VMH
and DMH in WT mice. Inset diagram is representative of VTA
cannulation placement with the arrow indicating the tip of the
guide cannula; the injector extends 1 mm further for injections. A,
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c-Fos IR in response to intra-VTA saline. B, c-Fos IR is markedly
increased in the VMH and DMH in response to intra-VTA
AM251. Scale bar, 100 mm.
Found at: doi:10.1371/journal.pone.0002202.s004 (1.04 MB TIF)
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